Home › Funds › Sessa Capital IM, L.P. › RNA

Sessa Capital IM, L.P. position in RNA

ATRIUM THERAPEUTICS INC · Health Care

Sessa Capital IM, L.P. reported holding 1,500,000 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$20.2M, representing 0.34% of its reported portfolio and ranking #24 among its reported holdings. Sessa Capital IM, L.P. has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)1.50M sh
Reported value held$20.18M
Portfolio Weight0.34%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Sessa Capital IM, L.P.'s RNA position evolved

Sessa Capital IM, L.P. first disclosed a stake in RNA in Q1 2026 at 551,391 shares (US$7.4M). The position peaked in Q2 2026 at 1,500,000 shares, worth US$20.2M. Across 2 filings, Sessa Capital IM, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,500,000 shares valued at US$20.2M — an increase of 948,609 shares quarter over quarter.. Notable position changes include a 172% increase in Q2 2026 (shares fell 38% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 551.39K $7.37M New
Q2 2026 1.50M $20.18M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RNA and 13F data

RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 116 other funds we track also report a position in RNA — the largest reported positions include CRCM LP (US$8.6M), TIG Advisors, LLC (US$7.6M), Arbiter Partners Capital Management LLC (US$3.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RNA

All RNA fund holders →

FAQ

How long has Sessa Capital IM, L.P. held RNA?

Sessa Capital IM, L.P. has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Sessa Capital IM, L.P.'s current position in RNA?

As of Q2 2026, Sessa Capital IM, L.P. holds 1.50M shares of RNA (ATRIUM THERAPEUTICS INC), valued at $20.18M, representing 0.34% of its reported portfolio and ranking #24.

Has Sessa Capital IM, L.P. been buying or selling RNA?

In the latest 13F filing (Q2 2026), Sessa Capital IM, L.P. increased its position in RNA. The position peaked in Q2 2026 at 1.50M shares.

Which other funds hold RNA?

Other major institutional holders of RNA include CRCM LP, TIG Advisors, LLC, Arbiter Partners Capital Management LLC, among 116 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.